Senior Vice President of Operations, Chief Financial Officer, and Treasurer
Mr. Arcudi joined the Company in 2007 as Chief Financial Officer. From 2003 to 2007, he served as Vice President of Finance and Administration and Treasurer for Peptimmune, Inc. and was responsible for all financial business and operations. Prior to joining Peptimmune, Mr. Arcudi was Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation from 2000 to 2003 and Director of Finance Business Planning and Operations International at Genzyme Corporation from 1998 to 2000. Prior to joining Genzyme, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation, and General Motors Corporation.
Mr. Arcudi received a Master of Business Administration from Bryant College and a Bachelor of Science degree in accounting and information systems from the University of Southern New Hampshire.
Vice President, Human Resources
Jill Conwell joined Idera as Vice President, Human Resources in February 2015. Prior to joining Idera, she served as Senior Human Resources Director at Shire Pharmaceuticals, where she partnered with business leaders in many segments of that company in aligning their organization strategy, structure, and plans with the overall business strategy. Prior to joining Shire, Ms. Conwell held roles of increasing responsibility at Accenture in that company’s Health & Life Sciences Consulting practices and with MacDermid, Inc.
Ms. Conwell holds a Bachelor of Science degree in chemical engineering from the University of Virginia and an MBA from the Wharton School at the University of Pennsylvania.
Vice President, Investor Relations and Corporate Communications
Robert Doody Jr. joined Idera as Vice President of Investor Relations and Corporate Communications in December 2014. Previously, Mr. Doody served as ViroPharma Incorporated’s Director of Investor Relations from May 2006 to January 2014. During his tenure at ViroPharma, the company was routinely recognized for excellence in investor relations. Mr. Doody began his communications career with Dorland Sweeney Jones, a health care public relations firm in Philadelphia.
Mr. Doody earned his Bachelor of Arts degree in communications from Rowan University in 2002 after having served honorably in the United States Navy.
Senior Vice President, Business Development and Strategic Planning
Clayton Fletcher joined Idera as Senior Vice President of Business Development and Strategic Planning in January 2015. Prior to joining Idera, Mr. Fletcher served as Vice President, Business Development & Project Management at ViroPharma from June 2005 to January 2014 and as a management team member from January 2011 to January 2014. In 2003, he assumed the position of Director Business Development and Project Management. Mr. Fletcher joined ViroPharma in April 2001 as Project Leader. From 1997 until 2001, he was Senior Project Manager at SmithKlineBeecham Pharmaceuticals. From 1996 until 1997, Mr. Fletcher was Project Scientist at Becton-Dickson and Company. From 1993 until 1996, he held positions with increasing responsibilities at Intracel Corporation. From 1991 to 1993, he was Senior Associate Scientist at Centocor Inc.
Mr. Fletcher received Bachelor of Science and Master of Science degrees in biology from Wake Forest University.
Senior Vice President, Chief Medical Officer
Dr. Horobin joined the company as Senior Vice President and Chief Medical Officer in November 2015. Prior to joining Idera, Dr. Horobin was most recently the Chief Medical Officer of Verastem,Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Additionally, Dr.Horobin held several roles of increasing responsibility at global pharmaceutical corporations suchas Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the global Oncology business unit’slaunch which included the launches of Taxotere® (docetaxel) in breast cancer andCampto/Camptosar® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venturewith Chugai to launch Granocyte® (lenograstim). Prior, Dr. Horobin played significant leadershiproles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban® andRelafen®/Reliflex®. Dr. Horobin received her medical degree from the University of Manchester,England.
Chief Executive Officer
Vincent Milano joined Idera as Chief Executive Officer in December 2014. Mr. Milano most recently served as Chairman, President, and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. Under his stewardship, ViroPharma became a leading developer of innovative therapies for rare diseases, with the approval and commercialization of its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe. Mr. Milano joined ViroPharma in 1996 and served as Vice President, Chief Financial Officer, and Treasurer from 1997 to 2006 before becoming Chief Executive Officer. He was instrumental in building the company, including leading efforts to raise nearly $900 million in capital, as well as acquisitions of Lev Pharmaceuticals and the drug Vancocin from Eli Lilly. In addition, he played critical roles in business development and investor relations activities for ViroPharma, and contributed significantly to establishing the strategic focus of the company. Prior to joining ViroPharma, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.
Mr. Milano currently serves on the Boards of Directors of Spark Therapeutics, Vanda Pharmaceuticals, and VenatoRx. He received his Bachelor of Science degree in accounting from Rider College.
Senior Vice President, Early Development
Dr. Yingling joined the company as Senior Vice President, Early Development in February 2017. Prior to joining Idera, Dr. Yingling was most recently the Chief Scientific Officer of Bind Therapeutics, Inc. Prior to his tenure at Bind Therapeutics, Dr. Yingling served as Vice President of Oncology Discovery and Translational Research at Bristol Myers Squibb and Company. In addition to his tenures at Bind Therapeutics and Bristol Myers Squibb & Company, Dr. Yingling had spent over a decade leading significant oncology development activities as well as drug candidate identification and M&A activities at Eli Lilly and Company. Dr. Yingling received his Ph.D. from Duke University and his Bachelor of Science from the College of William and Mary.
Julian C. Baker was appointed a member of the Company’s Board in March 2014. Mr. Baker is a Managing Partner of Baker Brothers Investments, which he founded in 2000 with his brother, Felix J. Baker, Ph.D. The firm manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch family. He holds an A.B., magna cum laude, from Harvard University.
Chairman of the Board
James Geraghty was appointed a member of the Board of Directors and Chairman of the Board in July 2013. Currently an Entrepreneur-in-Residence at Third Rock Ventures, Mr. Geraghty served as Senior VP, North America Strategy and Business Development at Sanofi, where he was a member of the Office of the CEO. Prior to joining Sanofi, he spent 20 years at Genzyme Corporation, where he helped introduce rare disease therapies around the world. His roles included Senior VP; President of Genzyme Europe, where he oversaw several new product launches; and General Manager of Genzyme’s cardiovascular business, where he guided the development of a recently approved antisense product. Mr. Geraghty also led strategic in-licensing transactions and divestitures. He was previously Chairman, President, and CEO of Genzyme Transgenics Corporation (now Revo Biologics), which he founded and took public. He also serves as Chairman of the Board of Juniper Pharmaceuticals and as a trustee of the Joslin Diabetes Center. He holds a J.D. from the Yale Law School, a Master of Science from the University of Pennsylvania, and a Bachelor of Arts degree from Georgetown University.
Mark Goldberg was appointed a member of the Company’s Board in January 2014. He served as a director of Synageva Biophamra from 2008 to 2011, stepping down to become a member of the executive management team from 2011 to 2014, rising to Executive Vice President, Medical and Regulatory Strategy during a portion of 2014. In late 2014 he stepped down from the executive management team and continued to be employed part-time, contributing to medical and regulatory strategy until leaving upon the acquisition by Alexion. Before joining the management team at Synageva, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 to 2011, most recently as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health. He was also the Chairman of Genzyme’s Early Product Review Board. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme®, and Lumizyme®. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Institute, where he still holds appointments. Dr. Goldberg is a part-time Associate Professor of Medicine at Harvard Medical School. Additionally, he has been a member of the Board of Directors of Immunogen, where he has served on the governance and nominating committee since November 2011; a member of the Board of Directors of Glycomimetics since 2014; a member of the Board of Directors of aTyr Pharma and Blueprint Medicines since earlier in 2015; and a member of the Board of Directors of the New England Division of the American Cancer Society since 2010. Dr. Goldberg received his A.B. from Harvard College and holds a Doctor of Medicine degree from Harvard Medical School. He was on the Brigham and Women’s Hospital medical housestaff from 1981 to 1984 and completed his hematology/oncology fellowship at Brigham and Women’s Hospital and the Dana Farber Cancer Institute. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers.
Maxine Gowen was appointed a member of the Company’s Board in January 2016. Dr. Gowen is the founding President and CEO of Trevena. Prior to this Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the board of directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989-1992. She has authored more than 100 refereed scientific publications.
Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, received a Ph.D. in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen also serves on the Board of Directors of Akebia Therapeutics (AKBA) and of the state and national biotechnology industry associations, PA BIO and BIO.
Chief Executive Officer
Vincent Milano joined Idera as Chief Executive Officer in December 2014. He most recently served as Chairman, President, and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. Under his stewardship, ViroPharma became a leading developer of innovative therapies for rare diseases, with the approval and commercialization of its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe. Mr. Milano currently serves on the Boards of Directors of Spark Therapeutics, Vanda Pharmaceuticals, and VenatoRx. He received his Bachelor of Science degree in accounting from Rider College.
Kelvin M. Neu was appointed a member of the Company’s Board in March 2014. Dr. Neu is a Managing Director of Baker Brothers Investments. The firm manages long-term investment funds focused on publicly traded life sciences companies, for major university endowments and foundations. He holds an A.B., summa cum laude, in molecular biology from Princeton University and an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology. He also trained for three years in the immunology Ph.D. program at Stanford University.
William S. Reardon was appointed a member of the Company’s Board in 2002 and served as Lead Director from 2010 to 2013. Mr. Reardon is a retired audit partner at PricewaterhouseCoopers LLP (PwC), where he led the Life Science Industry Practice for New England and the Eastern United States. He worked with numerous life science companies, including Genzyme, Vertex, Sepracor, and Cubist Pharmaceuticals. As an SEC Consulting Partner for PwC, he worked closely with SEC staff. Mr. Reardon also serves as a director and Audit Committee Chairman for Synta Pharmaceuticals, Inc. He has also served on the Board of the Emerging Companies Section of Biotechnology Industry (BIO) and the Board of Directors of the Massachusetts Biotechnology Council (MBC).
Dr. Anderson is the Program Director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at the Dana-Farber Cancer Institute. Dr. Anderson also is a Professor of Medicine at Harvard Medical School. Dr. Anderson also serves as the Vice President of the American Society of Hematology (ASH).